Cationic lipid-conjugated dexamethasone as a selective antitumor agent.
about
Dexamethasone suppresses the growth of human non-small cell lung cancer via inducing estrogen sulfotransferase and inactivating estrogen.Meta-analysis of the effects of oral and intravenous dexamethasone premedication in the prevention of paclitaxel-induced allergic reactions.PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome.Combination of cationic dexamethasone derivative and STAT3 inhibitor (WP1066) for aggressive melanoma: a strategy for repurposing a phase I clinical trial drug.Nanomedicine for cancer diagnosis and therapy: advancement, success and structure-activity relationship.Copper-Free 'Click' Chemistry-Based Synthesis and Characterization of Carbonic Anhydrase-IX Anchored Albumin-Paclitaxel Nanoparticles for Targeting Tumor Hypoxia.
P2860
Cationic lipid-conjugated dexamethasone as a selective antitumor agent.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
Cationic lipid-conjugated dexamethasone as a selective antitumor agent.
@en
type
label
Cationic lipid-conjugated dexamethasone as a selective antitumor agent.
@en
prefLabel
Cationic lipid-conjugated dexamethasone as a selective antitumor agent.
@en
P1476
Cationic lipid-conjugated dexamethasone as a selective antitumor agent
@en
P2093
Rajkumar Banerjee
Samaresh Sau
P304
P356
10.1016/J.EJMECH.2014.06.051
P577
2014-06-25T00:00:00Z